A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice

Archives of Virology

Volumn 159, Issue 10, 2014, Pages 2597-2604

  Izquierdo, Alienys ^a   García, Angélica ^a   Lazo, Laura ^b   Gil, Lázaro ^b   Marcos, Ernesto ^b   Alvarez, Mayling ^a   Valdés, Iris ^b   Hermida, Lisset ^b   Guillén, Gerardo ^b   Guzmán, María G ^a  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; DENGUE VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G; LPDA PROTEIN, NEISSERIA MENINGITIDIS; NEUTRALIZING ANTIBODY; OUTER MEMBRANE PROTEIN; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CLASSIFICATION; DENGUE; DENGUE VIRUS; DISEASE MODEL; FEMALE; GENETICS; IMMUNIZATION; IMMUNOLOGY; MOUSE; NEISSERIA MENINGITIDIS; SECRETION (PROCESS); VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BACTERIAL OUTER MEMBRANE PROTEINS; CAPSID PROTEINS; CELLS, CULTURED; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 84907688597     PISSN: 03048608     EISSN: 14328798     Source Type: Journal    
DOI: 10.1007/s00705-014-2115-2     Document Type: Article

References (39)

1. Guzman MG, Kouri G (2002) Dengue: an update. Lancet Infect Dis 2(1):33–42
2. Wallace D, Canouet V, Garbes P, Wartel TA (2013) Challenges in the clinical development of a dengue vaccine. Curr Opin Virol. doi:10.1016/j.coviro.2013.05.014
3. Halstead SB, O’Rourke EJ (1977) Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265(5596):739–741
4. Rothman AL (2010) Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr Top Microbiol Immunol 338:83–98
5. Swaminathan S, Batra G, Khanna N (2010) Dengue vaccines: state of the art. Expert Opin Ther Pat 20(6):819–835
6. Hermida L, Rodriguez R, Lazo L, Bernardo L, Silva R, Zulueta A, Lopez C, Martin J, Valdes I, Del Rosario D, Guillen GE, Guzman MG (2004) A fragment of the Envelope protein from Dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol Appl Biochem 39(1):107–114
7. Hermida L, Rodriguez R, Lazo L, Silva R, Zulueta A, Chinea G, Lopez C, Guzman MG, Guillen G (2004) A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods 115(1):41–49 pii: S0166093403003070
8. Izquierdo A, Bernardo L, Martin J, Santana E, Hermida L, Guillen G, Guzman MG (2008) Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res 138(1–2):135–138. doi:10.1016/j.virusres.2008.08.008
9. Lazo L, Zulueta A, Hermida L, Blanco A, Sanchez J, Valdes I, Gil L, Lopez C, Romero Y, Guzman MG, Guillen G (2009) Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol Appl Biochem 52(Pt 4):265–271
10. Bernardo L, Izquierdo A, Alvarez M, Rosario D, Prado I, Lopez C, Martinez R, Castro J, Santana E, Hermida L, Guillen G, Guzman MG (2008) Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antivir Res 80(2):194–199
11. Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C, Sierra Bde L, Martinez R, Rodriguez R, Zulueta A, Perez AB, Lazo L, Rosario D, Guillen G, Guzman MG (2006) A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24(16):3165–3171. doi:10.1016/j.vaccine.2006.01.036
12. Valdes I, Bernardo L, Gil L, Pavon A, Lazo L, Lopez C, Romero Y, Menendez I, Falcon V, Betancourt L, Martin J, Chinea G, Silva R, Guzman MG, Guillen G, Hermida L (2009) A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 394(2):249–258. doi:10.1016/j.virol.2009.08.029
13. Zulueta A, Hermida L, Lazo L, Valdes I, Rodriguez R, Lopez C, Silva R, Rosario D, Martin J, Guzman MG, Guillen G (2003) The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs. Biochem Biophys Res Commun 308(3):619–626
14. Marcos E, Gil L, Lazo L, Izquierdo A, Brown E, Suzarte E, Valdés I, García A, Méndez L, Guzmán MG, Guillén G, Hermida L (2013) Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus. Arch Virol 158(1):225–230
15. Clarke DH, Casals J (1958) Techniques for Hemagglutination and Hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg 7:561–573
16. Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N (1985) Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 22(2):250–254
17. Alvarez M, Rodriguez-Roche R, Bernardo L, Morier L, Guzman G (2005) Improved dengue virus plaque formation on BHK21 and LLCMK2 cells: evaluation of some factors. Dengue Bull 29:1–9
18. Brandler S, Ruffie C, Najburg V, Frenkiel MP, Bedouelle H, Desprès P, Tangy F (2010) Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 28:6730–6739
19. Lazo L, Gil L, Lopez C, Valdes I, Marcos E, Alvarez M, Blanco A, Romero Y, Falcon V, Guzmán MG, Guillén G, Hermida L (2010) Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus. Arch Virol 155(10):1587–1595
20. Lazo L, Gil L, López C, Valdés I, Blanco A, Pavón A, Romero Y, Guzmán MG, Guillén G, Hermida L (2012) A vaccine formulation consisting of nucleocapsid-like particles from Dengue-2 and the fusion protein P64k-domain III from Dengue-1 induces a protective immune response against the homologous serotypes in mice. Acta Tropica 124:107–112
21. Mune M, Rodriguez R, Ramirez R, Soto Y, Sierra B, Rodriguez Roche R, Marquez G, Garcia J, Guillen G, Guzman MG (2003) Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice. Arch Virol 148(11):2267–2273. doi:10.1007/s00705-003-0167-9
22. Simmons M, Murphy GS, Hayes CG (2001) Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 65(2):159–161
23. Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, Kanesa-Thasan N, Vaughn DW, Innis BL, Sun W (2003) Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69(6 Suppl):48–60
24. Vaughn DW (2000) Invited commentary: dengue lessons from Cuba. Am J Epidemiol 152(9):800–803
25. Putnak JR, de la Barrera R, Burgess T, Pardo J, Dessy F, Gheysen D, Lobet Y, Green S, Endy TP, Thomas SJ, Eckels KH, Innis BL, Sun W (2008) Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am J Trop Med Hyg 79(1):115–122
26. Guy B, Almond JW (2008) Towards a dengue vaccine: progress to date and remaining challenges. Comp Immunol Microbiol Infect Dis 31(2–3):239–252. doi:10.1016/j.cimid.2007.07.011
27. Hombach J, Cardosa MJ, Sabchareon A, Vaughn DW, Barrett AD (2007) Scientific consultation on immunological correlates of protection induced by dengue vaccines report from a meeting held at the World Health Organization 17–18 November 2005. Vaccine 25(21):4130–4139
28. Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, Harris E (2004) Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 78(6):2701–2710
29. Keating R, Yue W, Rutigliano JA, So J, Olivas E, Thomas PG, Doherty PC (2007) Virus-specific CD8+T cells in the liver: armed and ready to kill. J Immunol 178:2737–2745
30. Welsh RM, Selin LK, Szomolanyi-Tsuda E (2004) Immunological memory to viral infection. Annu Rev Immunol 22:23.1–23.33
31. Mongkolsapaya J, Duangchinda T, Dejnirattisai W, Vasanawathana S, Avirutnan P, Jairungsri A, Khemnu N, Tangthawornchaikul N, Chotiyarnwong P, Sae-Jang K, Koch M, Jones Y, McMichael A, Xu X, Malasit P, Screaton G (2006) T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J Immunol 176(6):3821–3829 pii: 176/6/3821
32. van der Most RG, Murali-Krishna K, Ahmed R (2003) Prolonged presence of effector-memory CD8 T cells in the central nervous system after dengue virus encephalitis. Int Immunol 15(1):119–125
33. van Der Most RG, Murali Krishna K, Ahmed R, Strauss JH (2000) Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J Virol 74(17):8094–8101
34. Gil L, Lopez C, Blanco A, Lazo L, Martin J, Valdes I, Romero Y, Figueroa Y, Guillen G, Hermida L (2009) The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol 22(1):23–30. doi:10.1089/vim.2008.0063
35. Moi ML, Takasaki T, Kurane I (2013) Efficacy of tetravalent dengue vaccine in Thai schoolchildren. Lancet 30(381):9872
36. Mota J, Acosta M, Argotte R, Figueroa R, Mendez A, Ramos C (2005) Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 23(26):3469–3476. doi:10.1016/j.vaccine.2004.12.028
37. Lazo L, Hermida L, Zulueta A, Sanchez J, Lopez C, Silva R, Guillen G, Guzman MG (2007) A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine 25(6):1064–1070. doi:10.1016/j.vaccine.2006.09.068
38. Guzman MG, Hermida L, Bernardo L, Ramirez R, Guillen G (2010) Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 9(2):137–147. doi:10.1586/erv.09.139
39. Gil L, Bernardo L, Pavon A, Izquierdo A, Valdes I, Lazo L, Marcos E, Romero Y, Guzman MG, Guillen G, Hermida L (2012) Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice. J Gen Virol 93(Pt 6):1204–1214. doi:10.1099/vir.0.037721-0